Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-7-7
|
| pubmed:abstractText |
Despite the use of conventional chemoprophylaxis regimens, patients receiving unrelated-donor BMT are at high risk of developing severe acute GVHD. We evaluated a prophylactic regimen combining CsA, MTX and anti-CD5-ricin A chain immunotoxin (H65-RTA) in 31 patients; pentoxifylline was also given to reduce the anticipated nephrotoxicity of CsA. In most cases, planned doses of CsA, MTX and H65-RTA were given (i.e. to 77%, 77% and 93% of patients, respectively). Although fluid retention requiring diuretic therapy was frequent, only 1 patient had a > 10% unexplained increase in body weight during the first 21 days post-BMT. Also, while significant increase of the baseline serum creatinine was noted in 7 patients, none required dialysis. One patient suffered a reversible allergic reaction to the immunotoxin; no other side effects attributable to this regimen were observed. All but 2 patients engrafted (1 died of fungemia on d + 19 and the other had persistent leukemia) and no late graft failures were observed. Seventeen patients developed acute GVHD grade > or = II (probability, 58% [95% CI 41-76%]); 7 had grade > or = III (probability, 24% [95% CI 12-43%]). In the 27 patients who achieved stable engraftment and have survived beyond d + 100, the 3-year probability of developing chronic GVHD was 66% (95% CI 48-84%). As of the last follow-up prior to 01 May 1994, 13 patients are alive in CR and one in relapse; 9 of these patients are off all immunosuppressives and well. Four other patients relapsed and died, and 13 died of other transplant-related causes.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD5,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
213-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7539667-Adolescent,
pubmed-meshheading:7539667-Adult,
pubmed-meshheading:7539667-Antigens, CD,
pubmed-meshheading:7539667-Antigens, CD5,
pubmed-meshheading:7539667-Bone Marrow Transplantation,
pubmed-meshheading:7539667-Child,
pubmed-meshheading:7539667-Child, Preschool,
pubmed-meshheading:7539667-Cyclosporine,
pubmed-meshheading:7539667-Drug Administration Schedule,
pubmed-meshheading:7539667-Female,
pubmed-meshheading:7539667-Follow-Up Studies,
pubmed-meshheading:7539667-Graft Survival,
pubmed-meshheading:7539667-Graft vs Host Disease,
pubmed-meshheading:7539667-Histocompatibility Testing,
pubmed-meshheading:7539667-Humans,
pubmed-meshheading:7539667-Immunotoxins,
pubmed-meshheading:7539667-Infant,
pubmed-meshheading:7539667-Male,
pubmed-meshheading:7539667-Methylprednisolone,
pubmed-meshheading:7539667-Middle Aged
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
|
| pubmed:affiliation |
Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Canada.
|
| pubmed:publicationType |
Journal Article
|